Lifestyle

For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3In...

Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA...

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 ––...

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for...

JERUSALEM, Feb. 26, 2026 /PRNewswire/ -- P-Cure, a leader in compact proton therapy solutions, has announced the successful completion of...

Registration is now open for the CAPABLE sessions in Farmington Hills, Grand Blanc and DetroitDETROIT, Feb. 26, 2026 /PRNewswire/ -- The...

International Cloud Computing Awards Program Announces its WinnersWACO, Texas, Feb. 26, 2026 /PRNewswire/ -- AxisCare, a leading provider in home care management...

A Data-Backed Cultural Campaign Reframing How We Speak About Growing OlderNEW YORK, Feb. 26, 2026 /PRNewswire/ -- Following a full-page open...

MONTRÉAL, Feb. 26, 2026 Quebecor Inc. ("Quebecor" or the "Corporation") today reported its consolidated financial results for the fourth quarter and...

SEOUL, South Korea, Feb. 26, 2026 /PRNewswire/ -- CJ BIO announced the publication of clinical research findings on its postbiotic...